How to best book patient appointments in rheumatology clinic? Should these be scheduled every 3 or 4 months regardless of patient status? Should they be scheduled by patient need or disease activity?
Dr. John Cush RheumNow
4 years 10 months ago
Long Term Steroid Use in RA - Matters of the Heart: Dr. Mrinalini Dey ( @DrMiniDey) discusses abstract #1428 presented at the #ACR21 annual meeting.
https://t.co/E6RSlPAuRT https://t.co/QBhKD855aH
Dr. John Cush RheumNow
4 years 10 months ago
This podcast is devoted to discussing patient satisfaction and factors important in their willingness or unwillingness (resistance) to change therapies.
https://t.co/eVLlD8gEIM https://t.co/B24NWnGLHu
Dr. John Cush RheumNow
4 years 10 months ago
ICYMI: Type 1 and Type II Lupus — Patient Perspectives: Dr. Mehta ( @bella_mehta) interviews Dr. Clowse about abstract #1277 presented at the #ACR21 annual meeting
https://t.co/2w1Lwwhplf https://t.co/4sJR6DG0q0
Dr. John Cush RheumNow
4 years 10 months ago
ICYMI: JAKi Safety: Dr. Aurelie Najm ( @AurelieRheumo) interviews Dr. Choy about JAKi safety data, including abstracts #0958, #1940 and #1941 presented at the #ACR21 annual meeting.
https://t.co/LOM8zz62Pm https://t.co/83HRCZdtfE
Dr. John Cush RheumNow
4 years 10 months ago
ICYMI: Updates on New Treatments for SpA: Drs. Antoni Chan ( @synovialjoints) interviews Dr. Laura Coates discuss a number of studies related to new treatments for SpA presented at the #ACR21 annual meeting.
https://t.co/aCK1RRvTaW https://t.co/X1TlY88Jng
Dr. John Cush RheumNow
4 years 10 months ago
ICYMI: Perspectives on CV safety: JAK inhibitor (Tofacitinib) and TNF inhibitors
https://t.co/g5FirIK9Af https://t.co/63s7IaKhl7
Dr. John Cush RheumNow
4 years 10 months ago
ICYMI: Filgotinib (Jyseleca) was approved by European Commission approved for EU use in adults with moderately to severely active Ulcerative colitis (not responding to conventional therapy or a biologic). Rec based on Phase 2b/3 SELECTION trial. https://t.co/9VbCJse6Tr
Dr. John Cush RheumNow
4 years 10 months ago
ICYMI: An Old Friend – Methotrexate in Psoriatic Arthritis
Methotrexate (MTX) remains one of our most used and reliable tools against a variety of rheumatic diseases, particularly in the care of peripheral arthritis such as PsA.
https://t.co/kJdQ9Pd67v
#ACR21 @_Castillo_Pedro https://t.co/lpvZJaPcYd
Dr. John Cush RheumNow
4 years 10 months ago
Find all our #ACR21 podcast coverage here.
https://t.co/ZcWxysfoY1 https://t.co/mKOX4suJYi
Dr. John Cush RheumNow
4 years 10 months ago
ICYMI: Drs. Jack Cush and the RheumNow Faculty Drs. David Liew, Swetha Ann Alexander, Meral El Ramahi, Mrinalini Dey and Robert Chao, discuss highlights from Day 2 at the #ACR21 meeting.
https://t.co/ZaXlhyEKwY
@drdavidliew @swethaann23 @MeralElRamahiMD @DrMiniDey @doctorRBC https://t.co/TNEJUEIRc4
Dr. John Cush RheumNow
4 years 10 months ago
ICYMI: Emerging Therapies in Psoriatic Arthritis: Drs. Antoni Chan ( @synovialjoints) interviews Dr. FitzGerald about abstract #0490 and other PsA highlights being presented at the #ACR21 annual meeting.
https://t.co/1v8WhMkRHr https://t.co/UbqGkbupUM

